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Abstract
OBJECTIVES The aim of this study was to 
determine the effect of pharmacist intervention on 
lifestyle modifications and pharmacological treatment in 
overweight and obese patients suffering from metabolic 
syndrome. 
METHOD Patients were recruited from the community 
setting according to the International Diabetes Federation 
definition inclusion criteria for metabolic syndrome. 
Anthropometric and biochemical tests were performed 
at baseline (t=0). Patients were assessed for medication 
compliance, occurrence of side-effects, lifestyle and risk 
factors using a questionnaire. Patients were re-assessed 
three months after pharmacist intervention (t=1). 
KEY FINDINGS A total of 35 patients participated 
in the study. Following pharmacist intervention there was 
a statistically significant improvement in compliance to 
medications (p=0.005) and statistically significant reduction 
in occurrence of side-effects (p=0.009), weight (p=0.005), 
waist circumference (p=0.000), body mass index (p=0.005), 
fasting blood glucose (p=0.015), total cholesterol (p=0.001) 
and triglyceride (p=0.000) levels. 
CONCLUSION Pharmacist intervention improved 
patient motivation to change their lifestyle. Pharmacists 
can play an important role in the management of metabolic 
syndrome.
KEYWORDS Lifestyle Modifications, Medication 
Compliance, Metabolic Syndrome, Pharmacist Intervention, 
Side-Effects 
Introduction
Metabolic syndrome is a major health threat and public 
health challenge causing a financial burden globally. It 
is associated with a five-fold increase in type 2 diabetes 
mellitus (T2DM) and a two-fold increase in cardiovascular 
complications.1 The primary cause of metabolic 
syndrome is obesity. Obesity causes insulin resistance or 
hyperinsulinaemia, which in turn results in activation of the 
sympathetic nervous system and an increase in appetite 
and over-eating. It also exerts negative actions on the 
cardiovascular and renal systems, resulting in hypertension. 
Hyperinsulinaemia enhances predisposition to T2DM and 
hypercholesterolaemia.2
Various institutions have defined metabolic syndrome, 
however the one most commonly used is the International 
Diabetes Federation (IDF) definition which states that 
obesity is a criterion to classify patients as suffering from 
metabolic syndrome. Obesity is measured using waist 
circumference (WC), however if body mass index is > 30 kg/
m² central obesity can be assumed and WC measurement 
is not required. This definition also states that patients also 
need to be suffering from two of the following conditions 
namely raised triglycerides, reduced high-density 
lipoprotein cholesterol (HDL-C), raised blood pressure (BP) 
and/or raised fasting plasma glucose (FBG) and are receiving 
treatment for these conditions.3
The aim of this study was to determine the effect of 
pharmacist intervention on lifestyle modifications and 
pharmacological treatment in overweight and obese 
patients suffering from metabolic syndrome.1 
Method
Approval from the University of Malta Research Ethics 
Committee was granted. Thirty-five patients were recruited 
by means of posters displayed in prominent places at a 
community pharmacy clinic and using flyers which were 
personally distributed to obese patients. Informed consent 
was obtained from each patient prior to pharmacist 
intervention. The inclusion criteria were: WC ≥ 94cm in 
males and ≥ 80cm in females and suffering from two or all 
of the following conditions, namely T2DM, hypertension 
and hypercholesterolaemia, according to the IDF definition.
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During the pre-intervention (t=0), a questionnaire was 
administered to patients to collect information about medical 
check-ups and medication-taking patterns, occurrence of 
side-effects, self-monitoring of blood pressure (BP), blood 
glucose and cholesterol, family and social history as well 
as dietary and exercise patterns. Patients’ anthropometric 
and biochemical parameters were measured. WC and 
height measurements were taken using a measuring tape, 
with WC measured mid-way between the lower margin of 
the last palpable rib and the top of the iliac crest. Weight 
was recorded using the Beurer® BF Limited Edition 2013 
electronic scale. The point-of-care (POC) Beurer® BM 55 BP 
monitor was used to obtain systolic and diastolic BP and 
pulse readings. The POC AccuTrend® Plus device was used 
to quantitatively measure blood triglycerides (TGs), blood 
total cholesterol (TC) and fasting blood glucose (FBG). 
Subsequently pharmacist intervention was undertaken by 
the investigator (SLM) where patients were advice on diet 
and exercise was provided and information booklets on 
metabolic syndrome, cardiovascular diseases, cholesterol, 
diabetes, diet, exercise and obesity were given to patients. 
After three months, the patients were contacted by 
telephone and a post-intervention appointment was set 
(t=1). A questionnaire to assess change in treatment and 
lifestyle since the first intervention was administered. 
Measurement of anthropometric and biochemical 
parameters was repeated using the same equipment. 
Statistical analysis was performed with IBM SPSS® version 20. 
The chi-square (X2) test was used to assess the association 
between two categorical variables, the paired-sample t-test 
was used to compare the pre- and post-intervention results, 
the independent sample t-test was used to compare mean 
parameter scores between the two groups clustered by 
age or gender, and the Pearson correlation test was used to 
measure the strength of the relationship between any two 
anthropometric and/or biochemical parameters. A p value 
less than 0.05 was considered statistically significant.
Results
Out of the total 35 patients recruited, 31 were female 
and 4 were male. The mean age was 70 years, ranging 
from 41 to 86 years. The most common combination of 
metabolic syndrome components was hypertension and 
dyslipidaemia (n=18), followed by hypertension, diabetes 
and dyslipidaemia (n=9), hypertension and diabetes (n=6) 
and diabetes and dyslipidaemia (n=2). The most common 
medication prescribed for hypertension, dyslipidaemia 
and T2DM was perindopril (n=19), simvastatin (n=21) and 
metformin (n=16) respectively.
Prior to pharmacist intervention 14 out of the 35 patients 
experienced side-effects, where 9, 7 and 10 patients 
reported side-effects from their hypertension, T2DM and 
dyslipidaemia treatment respectively. Side-effects reported 
in patients suffering from hypertension included dizziness 
(n=4), increased frequency of urination (n=4) and swollen 
ankles (n=5). Patients on treatment for hyperglycaemia 
reported diarrhoea (n=5) and patients on treatment for 
dyslipidaemia reported musculoskeletal-related side-effects, 
including muscle weakness (n=4), muscle cramps (n=3) and 
muscle pain (n=3). After pharmacist intervention, 10 patients 
claimed to have stopped experiencing side-effects. The X2 
test showed a p-value of 0.009, implying that pharmacist 
intervention decreased incidence of side-effects (Table 1).
Pharmacist intervention improved patient motivation  
to change their lifestyle... Pharmacists can play an important role  
in the management of metabolic syndrome
Number of patients experiencing  
side-effects at t=0
Number of patients experiencing  
side-effects at t=1
Yes No Yes No
14 21 4 31
X2(1)=6.774, p=0.009
Table 1: Comparison of side-effect occurrence before (t=0) and after (t=1) pharmacist intervention (N=35)
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Number of patients compliant  
to medication at t=0
Number of patients compliant  
to medication at t=1
Yes No Yes No
20 15 30 5
X2(1)=7.778, p=0.005
Table 2: Comparison of medication compliance before (t=0) and after (t=1) pharmacist intervention (N=35)
Parameters t=0  (mean ± SD) t=1 (mean ± SD) p-value
Weight (kg) 78.65 ± 18.81 77.43 ± 18.26 0.005*
BMI (kg/m2) 31.37 ± 6.78 30.84 ± 6.30 0.005*
WC (cm) 104.34 ± 11.49 98.11 ± 11.33 0.000*
SBP (mmHg) 151.61 ± 23.10 147.30 ± 18.43 0.075
DBP (mmHg) 89.86 ± 11.30 88.13 ± 12.52 0.224
FBG (mmol/L) 5.45 ± 1.61 4.89 ± 1.61 0.015*
TC (mmol/L) 5.39 ± 0.9 5.05 ± 0.90 0.001*
TGs (mmol/L) 1.73 ± 1.13 1.45 ± 1.09 0.000*
*p-value < 0.05 is considered statistically significant; SD: Standard Deviation
Table 3: Comparison of anthropometric and biochemical parameters before (t=0) and after (t=1) pharmacist intervention 
(N=35)
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As regards medication compliance, before pharmacist 
intervention 15 patients stated that they rarely or 
occasionally miss a dose of their medication. The most 
common reasons for missing a dose were forgetfulness 
(n=11) and feeling well with or without medication 
(n=2). Patient compliance to medication increased post-
pharmacist intervention since the number of patients 
who stated that they miss a dose decreased to 5 (p=0.005) 
(Table 2). The anthropometric and biochemical findings are 
compared in Table 3. Mean weight, BMI, WC, FBG, TC and 
TGs decreased significantly in all patients after pharmacist 
intervention. The mean readings for systolic and diastolic 
BP decreased after pharmacist intervention, however 
improvement was not statistically significant (p>0.05).
Discussion
A study conducted by Tavares et al., stated that compliance 
to medications tends to be lower in patients with a higher 
number of comorbidities, especially elderly patients.4 Most 
patients who claimed to miss medication doses in this study 
claimed to do so due to forgetfulness (n=11). Given the 
age of the participants, cognitive impairment is expected. 
Tavares et al., stated that older people were found to be 
less compliant to their treatment due to forgetfulness and 
complicated dosage regimens.4
Occurrence of side-effects decreased significantly after 
pharmacist intervention, indicating that pharmacists could 
have an important role in advising patients on how to reduce 
and manage their side-effects. With their knowledge and 
expertise in pharmacology, pharmacists are in a position 
to effectively manage patients to reduce side-effects and 
increase medication compliance, improving quality of care. 
Furthermore, the findings indicate that pharmacists have 
an important role in promoting lifestyle changes through 
patient education and advice. 
This study is limited by the small sample size and challenges 
in patient recruitment since testing was invasive. 
Questionnaire responses may not be accurate since they 
depend on truthfulness of patients.
Conclusion
The findings indicate that pharmacists are in a position 
to play an important role in the management of patients 
suffering from metabolic syndrome through provision 
of advice and education about their disease states, 
beneficial effects of pharmacological treatment, side-
effects which can be expected and their prevention and 
effective management, as well as on lifestyle modifications. 
Pharmacists have the potential to reduce morbidity and 
mortality in patients suffering from metabolic syndrome.
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